<DOC>
	<DOCNO>NCT01304147</DOCNO>
	<brief_summary>The objective current study investigate safety efficacy single dose intranasal ( IN ) ketamine treatment-resistant depression ( TRD ) .</brief_summary>
	<brief_title>Intranasal Ketamine Treatment-Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1 . Male female patient , 2165 year ; 2 . Women childbearing potential must agree use medically accept mean contraception duration study ; 3 . Primary diagnosis major depressive disorder assess SCIDP ; 4 . Current depressive episode ; 5 . History failure respond least one ( 1 ) adequate pharmacotherapy trial current major depressive episode ; 6 . Subjects must score ≥ 30 IDSC30 Screening ≥ 24 Treatment Day # 1 # 2 ; 7 . Each subject must level understanding sufficient agree test examination require protocol must sign informed consent document ; 8 . Subjects must able identify family member , physician , friend participate Treatment Contract serve emergency contact . 1 . Women plan become pregnant , pregnant breastfeeding ; 2 . Any unstable medical illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic , immunologic , hematologic disease ; 3 . Clinically significant abnormal finding laboratory parameter , physical examination , ECG ; 4 . Lifetime history schizophrenia , schizoaffective disorder , bipolar disorder , OCD , mental retardation , pervasive developmental disorder , Tourette 's syndrome ; 5 . Drug alcohol abuse dependence within precede 6 month ; 6 . Lifetime abuse dependence ketamine phencyclidine ; 7 . Patients judge study investigator high risk suicide . 8 . Previous participation ketamine study Mount Sinai</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ketamine</keyword>
	<keyword>depression</keyword>
	<keyword>treatment resistance</keyword>
	<keyword>intranasal , antidepressant</keyword>
	<keyword>glutamate</keyword>
	<keyword>NMDA receptor</keyword>
</DOC>